Onyia Jude — SEC Form 4 filings
SEC reporting owner CIK 1894425. 21 Form 4 filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2024-02-02 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 9 filings — 109,075 shares, $14,785,142 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 49.
- Largest priced transaction: sale of 59,819 shares @ $130.46 ($7,803,688) in NEUROCRINE BIOSCIENCES INC, filed 2025-07-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Chief Scientific Officer | 18 | — | 10 legs · 109,075 sh · $14,785,142 | 46 |
| Voyager Therapeutics, Inc. (VYGR) | Director | 3 | — | — | 3 |
Form 4 filings — Onyia Jude
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 3,587 @ $0 · Tax withholding (F): 1,936 @ $156.22 | EDGAR |
| 2026-08-05 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Gift (G): 2,409 @ $0 | EDGAR |
| 2026-06-11 | 4 | Voyager Therapeutics, Inc. (VYGR) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Gift (G): 2,441 @ $0 | EDGAR |
| 2026-06-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 11,000 @ $84.74 · Sale (S): 11,000 @ $160.25 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 11,000 @ $84.74 · Sale (S): 11,000 @ $155.53 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Gift (G): 3,110 @ $0 | EDGAR |
| 2026-02-17 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,560 @ $0 · Tax withholding (F): 1,426 @ $123.10 · Option exercise (M): 2,690 @ $0 · Tax withholding (F): 1,452 @ $124.12 · Option exercise (M): 2,717 @ $0 · Tax withholding (F): 1,466 @ $124.12 · +7 more | EDGAR |
| 2026-02-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 238 @ $0 · Tax withholding (F): 142 @ $136.06 · Option exercise (M): 238 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 4,426 @ $0 · Tax withholding (F): 2,248 @ $152.16 · Option exercise (M): 4,426 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Gift (G): 1,470 @ $0 | EDGAR |
| 2025-08-07 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Gift (G): 3,116 @ $0 | EDGAR |
| 2025-07-11 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 59,819 @ $84.74 · Sale (S): 59,819 @ $130.46 · Option exercise (M): 59,819 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 20,362 @ $84.74 · Sale (S): 20,362 @ $130.13 · Option exercise (M): 20,362 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Voyager Therapeutics, Inc. (VYGR) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,717 @ $0 · Sale (S): 1,432 @ $116.83 · Option exercise (M): 2,690 @ $0 · Sale (S): 1,447 @ $116.75 · Grant/award (A): 54,645 (derivative) @ $0 · Grant/award (A): 10,241 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 238 @ $0 · Sale (S): 126 @ $152.97 · Option exercise (M): 238 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 4,426 @ $0 · Sale (S): 2,331 @ $126.29 · Option exercise (M): 4,426 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Voyager Therapeutics, Inc. (VYGR) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,432 @ $132.94 · Grant/award (A): 54,069 (derivative) @ $0 · Grant/award (A): 10,760 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 126 @ $141.94 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1894425 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →